Is Volitionrx going out of business?

VOLITIONRX LTD (VNRX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

VOLITIONRX LTD (VNRX) scores 13 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)

Five questions, kept separate

Survival - Critical

1-2 mo of estimated runway from 2026-06-30, based on $2.8M of cash and short-term investments against $35.5M of annual burn. Debt pressure is the other decisive risk.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

-77.6% net-cash backing support an extreme expectations pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• FCF margin: -1444.77%
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.08y
• Revenue CAGR (3Y): 77.98%
• Revenue growth YoY: -1.97% (YoY)
• Return on Assets: -308.88%
• Debt Maturity Runway: 85% long-term (Long-term focused)
• Cash Burn Deceleration: -388.22% QoQ improvement (Worsening)
• Price / Sales: 2.6x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-24.

Price as of 2026-09-07.